Background Any strategy for curing HIV infection must include a method to eliminate viral-infected cells. Based on our earlier proof-of-principle results targeting HIV-1 infected cells with radiolabeled antibody (mAb) to gp41 viral antigen, we embarked on identifying a suitable candidate mAb for preclinical development. Methodology/Principal Findings Among the several human mAbs to gp41 tested, mAb 2556 was found to have high affinity, reactivity with multimeric forms of gp41 present on both the surface of virus particles and cells expressing HIV-1 Env, and recognition of a highly conserved epitope of gp41 shared by all HIV-1 subtypes. Also, mAb 2556 was the best in competition with HIV-1+ serum antibodies, which is an extremely important consideration for efficacy in the treatment of HIV patients. When radiolabeled with alpha-emitting radionuclide 213-Bismuth (213Bi) - 213Bi-2556 efficiently and specifically killed ACH-2 human lymphocytes chronically infected with HIV-1, and HIV-1 infected human peripheral blood mononuclear cells (hPBMCs). The number of binding sites for 213Bi-2556 on the surface of the infected cells was >106. The in vivo experiments were performed in two HIV-1 mouse models – splenic and intraperitoneal. In both models, the decrease in HIV-1 infected hPBMCs from the spleens and peritoneum, respectively, was dose-dependent with the most pronounced killing of hPBMCs observed in the 100 μCi 213Bi-2556 group (P = 0.01). Measurement of the blood platelet counts and gross pathology of the treated mice demonstrated the lack of toxicity for 213Bi-2556. Conclusions/Significance We describe the preclinical development of a novel radiolabeled mAb reagent that could potentially be part of an HIV eradication strategy that is ready for translation into the clinic as the next step in its development. As viral antigens are very different from “self” human antigens - this approach promises high selectivity, increased efficacy and low toxicity, especially in comparison to immunotoxins.
References
[1]
Chun TW, Davey RT Jr, Ostrowski M, Shawn Justement J, Engel D, et al. (2000) Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 6: 757–761.
[2]
Chun TW, Fauci AS (1999) Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad U S A 96: 10958–10961.
[3]
Volberding PA, Deeks SG (2010) Antiretroviral therapy and the management of HIV infection. Lancet 376: 49–62.
[4]
Dieffenbach CW, Fauci AS (2011) Thirty Years of HIV and AIDS: Future challenges and opportunities. Ann Intern Med 154: 766–771.
[5]
Chaudry VK, Tamio M, Fuerst TR, FitzGerald DJ, Moss B, et al. (1988) Selective killing of HIV-infected cells by a recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature 335: 369–372.
[6]
Berger EA, Pastan I (2010) Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog 6: e1000803.
[7]
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, et al. (2010) Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. (2010) N Engl J Med 363: 1812–21.
[8]
Kreitman RJ (2006) Immunotoxins for Targeted Cancer Therapy. (2006) AAPS Journal 8: E532–E551.
[9]
Sharkey RM, Goldenberg DM (2006) Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 56: 226–243.
[10]
Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nature Rev Drug Discovery 3: 488–499.
[11]
Alduaij W, Illidge TM (2009) Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma. Curr Oncol Rep 11: 363–370.
[12]
Dadachova E, Nakouzi A, Bryan RA, Casadevall A (2003) Ionizing radiation delivered by specific antibody in therapeutic against a fungal infection. Proc Natl Acad Sci U S A 100: 10942–10947.
[13]
Dadachova E, Casadevall A (2009) Radioimmunotherapy of infectious diseases. Semin Nucl Med 39: 146–153.
[14]
Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, et al. (2006) Targeted Killing of Virally Infected Cells by Radiolabeled Antibodies to Viral Proteins. PLoS Med 3: e427.
[15]
Gorny MK, Xu J-Y, Gianakakos V, Karwowska S, Williams C, et al. (1991) Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein. Proc Natl Acad Sci U S A 88: 3238–3242.
[16]
Gorny MK, Gianakakos V, Sharpe S, Zolla-Pazner S (1989) Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A 86: 1624–1628.
[17]
Xu JY, Gorny MK, Palker T, Karwowska S, Zolla-Pazner S (1991) Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immuno-deficiency virus type 1, using ten human monoclonal antibodies. J Virol 65: 4832–4838.
[18]
Jeffs SA, Gorny MK, Williams C, Revesz K, Volsky B, et al. (2001) Characterization of human monoclonal antibodies selected with a hypervariable loop-deleted recombinant HIV-1(IIIB) gp120. Immunol Lett 79: 209–213.
[19]
Gigler A, Dorsch S, Hemauer A, Williams C, Kim S (1999) Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol 73: 1974–1979.
[20]
Gorny MK, Williams C, Volsky B, Revesz K, Cohen S, et al. (2002) Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize HIV-1 primary isolates from various clades. J Virol 76: 9035–9045.
[21]
Lindenbaum M, Perkins E, Csonka E, Fleming E, Garcia L, et al. (2004) A mammalian artificial chromosome engineering system (ACE System) applicable to biopharmaceutical protein production, transgenesis and gene-based cell therapy. Nuc Acid Res 32: e172.
[22]
Ho DD, Moudgil T, Alam M (1989) Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 321: 1621–1625.
[23]
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr (1984) Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 72: 77–89.
[24]
Mosier DE (1996) Viral pathogenesis in hu-PBL-SCID mice. Sem Immunol 8: 255–262.
[25]
Mosier DE, Gulizia RJ, Baird SM, Wilson DB, Spector DH, et al. (1991) Human immunodeficiency virus infection of human-PBL-SCID mice. Science 251: 791–794.
[26]
Mosier DE, Gulizia RJ, MacIsaac PD, Torbett BE, Levy JA (1991) Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 260: 689–692.
[27]
Vatakis DN, Bristol G, Wilkinson TA, Chow SA, Zack JA (2007) Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells. J Virol 81: 3574–3582.
[28]
Nyambi PN, Mbah HA, Burda S, Williams C, Gorny MK, et al. (2000) Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol 74: 7096–7107.
[29]
Pietzsch J, Scheid JF, Mouquet H, Seaman MS, Broder CC, et al. (2010) Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol 84: 5032–5042.
[30]
Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, et al. (2002) Targeted α particle immunotherapy for myeloid leukemia. Blood 100: 1233–1239.
[31]
Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, et al. (2010) Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging 37: 1335–1344.
[32]
Allen BJ, Raja C, Rizvi S, Li Y, Tsui W, et al. (2005) Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 4: 1318–1324.
[33]
Dadachova E, Bryan RA, Apostolidis C, Morgenstern A, Zhang T, et al. (2006) Interaction of radiolabeled antibodies with fungal cells and components of immune system in vitro and during radioimmunotherapy of experimental fungal infection. J Infect Dis 193: 1427–1436.
[34]
Uckun FM, Qazi S, Pendergrass S, Lisowski E, Waurzyniak B, et al. (2003) Structure-based design and engineering of a nontoxic recombinant pokeweed antiviral protein with potent-anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 47: 1052–1061.
[35]
Uckun FM, Qazi S, Pendergrass S, Lisowski E, Waurzyniak B, et al. (2002) In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5′-(p-bromophenyl methoxyalaninyl phosphate (stampidine) in mice. Antimicrob Agents Chemother 46: 3428–3436.
[36]
Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 50: 219–244.
